{
  "node_id": "eu-biosimilars-guideline-ema-2014",
  "title": "Biosimilar Development: Comparability Exercise, Quality Comparability, Non-Clinical Studies, Clinical PK/PD Studies, Efficacy/Safety and Immunogenicity Assessment",
  "domain": "Pharmaceuticals & Life Sciences",
  "version": "1.0.1",
  "last_updated": "2026-04-30",
  "bluf": "This guideline outlines the scientific principles for demonstrating biosimilarity between a proposed biosimilar and its reference biological medicinal product through a stepwise comparability…",
  "paywall": {
    "status": "LOCKED",
    "unlock_cost_usd": "0.01",
    "skyfire_id": "41779894-ece2-4163-9761-b3b1b76e19b0"
  },
  "crosswalks": {
    "_available_keys": [
      "nist_framework",
      "iso_standard",
      "industry_mapping",
      "ai_overlay_2026"
    ],
    "_note": "Full crosswalk values included in vault response"
  },
  "dependencies": [
    "ich-q10-pharmaceutical-quality-system-2008",
    "eu-gmp-annex-1-sterile-manufacture-2022",
    "fda-biosimilar-pathway-351k-biologics-competition-act"
  ],
  "primary_citations_count": 5,
  "workflow_steps_count": 10,
  "schema_fields_count": 11,
  "citation_preview": [
    "Scientific guidelines | European Medicines Agency (EMA) - EMA strongly encourages applicants and marketing authorisation holders to follow the guidelines featured on this page.",
    "Scientific guidelines | European Medicines Agency (EMA) - Applicants need to justify deviations from guidelines fully in their applications at the time of submission."
  ]
}